Evaluating the Effect of Mucinex 1200mg on Mucociliary and Cough Clearance During an Acute Respiratory Infection

Reckitt Benckiser LLC38 enrolled

Overview

The purpose of this research study is to explore the mechanism of action of Mucinex, an oral, over-the-counter, FDA approved expectorant in patients with acute respiratory tract infections.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Acute Respiratory Infection

Interventions

MucinexDRUG

Mucinex 1200mg (Guaifenesin) given as 2,600mg tablets, one time on day 1 of the study

PlaceboDRUG

Placebo given as 2 tablets

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Symptoms of cough, thickened mucus and chest congestion * Able to produce sputum * Non Smoker Exclusion Criteria: * Pregnant * Smokers * Fever above 101°F * Any chronic illness

Locations (1)

Center for Environmental Medicine, Asthma, and Lung Biology

Chapel Hill, North Carolina, United States

Outcomes

Primary Outcomes

Percent of Inhaled Radioactive Tracer Particles Cleared From Lungs

Percentage of inhaled radioactive tracer (Ave180Clear)

Time frame: 3 hours following inhalation of radioactive tracer particles

Secondary Outcomes

Guaifenesin AUC(0-3)

Time frame: 3 hours following dose administration

Assess Sputum Properties (Objective Measures) and Symptoms (Subjective Measures) After Treatment With Mucinex or Placebo.

Time frame: Within 10 days of developing symptoms associated with a respiratory tract infection

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.